Lv4
500 积分 2026-07-29 加入
Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation
1个月前
已完结
Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease
1个月前
已完结
Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD
1个月前
已完结
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
1个月前
已完结
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
1个月前
已完结
Risankizumab for Ulcerative Colitis
1个月前
已完结
皖公网安备34019202002308
